Skip to content
Events

Details

Hear from Steve Barnard about the latest Illumina innovations from library prep, sequencing, and analysis and learn how we are enabling transformative applications using multiomics. Niall Lennon, PhD from the Broad Institute of MIT will join Steve to provide insights into new Illumina technology.
Steve Barnard, PhD

Steve Barnard, PhD
Chief Technology Officer
Illumina

Steve Barnard, PhD

Niall Lennon, PhD
Chair and Chief Scientific Officer
Broad Clinical Labs, MIT

 

M-AMR-01684
Fill Out Form to Access Webinar

Your email address is never shared with third parties.

Date & Time
Nov 6, 2024
Topic
Instruments, Software & informatics
Watch Now

Related Events

Feb 26
Illumina’s Integrated Workflow for Rare and Undiagnosed Genetic Disease Research
Feb 26, 2025
Individuals suspected of having a rare disease often face a long search for an answer. With up to 80% of rare diseases being genetic or having a genetic subtype, it is imperative to interrogate the genome to find answers and shorten the diagnostic odyssey. This webinar provides an overview of the integrated workflow provided by Illumina for rare and undiagnosed diseases research. Starting from library prep to sequencing and informatics, Illumina empowers researchers to find the answers they seek in rare and undiagnosed disease research.
View Event
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see www.illumina.com/company/legal.html.

© 2025 Illumina, Inc. All rights reserved.